Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
21 July 2014Website:
http://www.matinasbiopharma.comNext earnings report:
27 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 00:49:13 GMTDividend
Analysts recommendations
Institutional Ownership
MTNB Latest News
Signs non-binding term sheet granting global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive fungal infections
Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript
Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Jody Cain - LHA IR Jerry Jabbour - CEO Terri Matkovits - CDO Terry Ferguson - CMO Keith Kucinski - CFO Conference Call Participants Julian Harrison - BTIG Operator Welcome to the Matinas BioPharma Third Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
Let's talk penny stocks, those under-five-dollar shares that buzz with potential. They're nimble, sensitive to the slightest news, and can pivot on a dime.
BEDMINSTER, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small oligonucleotides with its lipid nanocrystal (LNC) platform technology, announces that Jerome D. Jabbour, Chief Executive Officer, will present a company overview and hold meetings with institutional investors at two upcoming investment conferences:
Matinas Biopharma Holdings, Inc. (MTNB) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago.
BEDMINSTER, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announces that it will report first quarter 2023 financial results after market close on Wednesday, May 10, 2023. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
What type of business is Matinas BioPharma Holdings?
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It also offers MAT2501, an orally administered formulation of amikacin to treat chronic and acute bacterial infections, as well as non-tuberculosis mycobacterium. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases for the development of oral formulations of Gilead's remdesivir; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.
What sector is Matinas BioPharma Holdings in?
Matinas BioPharma Holdings is in the Healthcare sector
What industry is Matinas BioPharma Holdings in?
Matinas BioPharma Holdings is in the Biotechnology industry
What country is Matinas BioPharma Holdings from?
Matinas BioPharma Holdings is headquartered in United States
When did Matinas BioPharma Holdings go public?
Matinas BioPharma Holdings initial public offering (IPO) was on 21 July 2014
What is Matinas BioPharma Holdings website?
https://www.matinasbiopharma.com
Is Matinas BioPharma Holdings in the S&P 500?
No, Matinas BioPharma Holdings is not included in the S&P 500 index
Is Matinas BioPharma Holdings in the NASDAQ 100?
No, Matinas BioPharma Holdings is not included in the NASDAQ 100 index
Is Matinas BioPharma Holdings in the Dow Jones?
No, Matinas BioPharma Holdings is not included in the Dow Jones index
When was Matinas BioPharma Holdings the previous earnings report?
No data
When does Matinas BioPharma Holdings earnings report?
The next expected earnings date for Matinas BioPharma Holdings is 27 March 2025